Document is current
Any future updates will be listed below
-
Authors
Pareja, Fresia https://orcid.org/0000-0003-3748-8049
Ferrando, Lorenzo https://orcid.org/0000-0002-4025-7930
Lee, Simon S. K.
Beca, Francisco https://orcid.org/0000-0002-4409-012X
Selenica, Pier
Brown, David N.
Farmanbar, Amir
Da Cruz Paula, Arnaud
Vahdatinia, Mahsa https://orcid.org/0000-0002-9424-537X
Zhang, Hong
Zoppoli, Gabriele
Wen, Hannah Y.
Brogi, Edi https://orcid.org/0000-0003-4737-8468
Robson, Mark E. https://orcid.org/0000-0002-3109-1692
Razavi, Pedram https://orcid.org/0000-0003-4236-0576
Chandarlapaty, Sarat https://orcid.org/0000-0003-4532-8053
Weigelt, Britta https://orcid.org/0000-0001-9927-1270
Reis-Filho, Jorge S. https://orcid.org/0000-0003-2969-3173
- License Information
-
More Information
Article History
Received: 10 March 2020
Accepted: 22 September 2020
First Online: 14 October 2020
Competing interests
: J.S.R.-F. reports receiving personal/consultancy fees from Goldman Sachs and REPARE Therapeutics, membership of the scientific advisory boards of VolitionRx and Page.AI, and ad hoc membership of the scientific advisory boards of Roche Tissue Diagnostics, Ventana Medical Systems, Novartis, Genentech and InVicro, outside the scope of this study. P.R. reports consulting/advisory board for Novartis and institutional research support from Illumina and GRAIL, Inc. S.C. has received research support from Daichi Sankyo and consulting fees from Novartis, Sermonix, BMS, Context Therapeutics, Revolution Medicine, Paige AI, and Eli Lilly. G.Z. has received research support from ThermoFisher Scientific, AstraZeneka UK, and SIDRA Medicine. All other authors declare no competing interests.
